

STAT6061/STAT5008 – Causal Inference

Part 8. Causal Inference in Longitudinal and Survival Data

An-Shun Tai

*¹Department of Statistics
National Cheng Kung University*

*²Institute of Statistics and Data Science
National Tsing Hua University*

Longitudinal data

- Longitudinal data consist of **repeated observations of the same subjects over time**. This structure allows researchers to examine within-subject changes, assess temporal dynamics, and distinguish individual variability from population-level trends.

Note: In contrast to longitudinal data, cross-sectional data provide only a **snapshot of observations at a single point in time**, but they are often easier to collect, less costly, and useful for estimating prevalence and identifying associations in a population.

- Examples

Repeated measurements of blood pressure over several clinic visits; Annual cognitive test scores in an aging cohort study; Monthly HbA1c levels in diabetic patients; Student academic performance tracked across semesters; Weekly symptom reports in a clinical trial

- Common statistical methods

1. Linear mixed-effects models / Generalized linear mixed models
2. Generalized estimating equations
3. Growth curve models / Latent trajectory models
4. Marginal structural models / G-formula (**causal inference**)

Causal inference for longitudinal data

- In Parts 1 to 4, treatments, confounders (or covariates), and outcomes were all measured at a single time point.

(Note: Although each variable was observed only once, the actual measurement times may differ across variables.)


- In the longitudinal setting, data typically consist of:

- Time-varying confounders
- Time-varying treatments
- Time-varying (repeated) outcomes

- Notations for two time points (baseline $t = 0$ and follow-up $t = 1$)

- Y_0, Y_1 : Outcome at time 0 and time 1, respectively
- A_0, A_1 : Treatment or exposure at time 0 and time 1
- L_0, L_1 : Time-varying confounders at time 0 and time 1
- C : Baseline (time-invariant) confounder

(L_0 vs. C and L_1 vs. Y_0)



Post-treatment covariates

- A post-treatment covariate (L_1) is a variable that occurs after treatment and is associated with the outcome. While it can act as a time-varying confounder, not all post-treatment covariates change over time (time-invariant).
- Examples

(Truncation by Death)


In trials with severely ill patients, some may die before the outcome (like quality of life) is measured. The post-treatment covariate L_1 is a binary indicator of survival.

(Unemployment)

In job training studies, people are assigned to treatment or control and then report their employment status L_1 and wage Y . Here, L_1 indicates whether they are employed.

(Surrogate Endpoint)

In clinical trials, long-term outcomes (e.g., 30-year survival) are costly and time-consuming to measure. Researchers often use early, easier-to-measure variables called **surrogate endpoints**. For example, in HIV trials, **CD4 cell count** is used as a surrogate for long-term survival.



Conditioning on the post-treatment covariate

- A common but naive approach is to condition on the post-treatment covariates L_1 as if it were a baseline covariate.
- However, L_1 differs fundamentally from baseline covariates C because L_1 is generally affected by the treatment, while C is not.

- A general rule of thumb (Cochran, 1957; Rosenbaum, 1984):

Avoid conditioning on post-treatment covariates when estimating the ATE.

- Frangakis and Rubin (2002) offered a more formal explanation using the potential outcomes framework.

1. Suppose we ignore the baseline confounder C ; in that case, the exchangeability assumption is modified as follows:

$$\{Y(1), Y(0), L_1(1), L_1(0)\} \perp A$$

2. Conditioning on $L_1 = l$, we compute

$$\tau_L = \mathbb{E}(Y|A = 1, L_1 = l) - \mathbb{E}(Y|A = 0, L_1 = l)$$

- If L_1 is a baseline covariate, this comparison exactly reflects the conditional ATE.
- However, L_1 is a post-treatment covariates now, and the interpretation becomes problematic due to potential bias.

Conditioning on the post-treatment covariate (cont.)

3. Under the modified exchangeability assumption, we have

$$\mathbb{E}(Y|A = 1, L_1 = l) = \mathbb{E}(Y(1)|A = 1, L_1(1) = l) = \mathbb{E}(Y(1)|L_1(1) = l)$$

and

$$\mathbb{E}(Y|A = 0, L_1 = l) = \mathbb{E}(Y(0)|A = 0, L_1(0) = l) = \mathbb{E}(Y(0)|L_1(0) = l)$$

Therefore, τ_L correspond to the contrast

$$\mathbb{E}(Y(1)|L_1(1) = l) - \mathbb{E}(Y(0)|L_1(0) = l)$$

which compares the distributions of $Y(1)$ and $Y(0)$ cross different subsets of units—those defined by the post-treatment values $L_1(1) = l$ and $L_1(0) = l$, respectively.

- In general, comparisons conditional on $L_1 = l$ do not have a valid causal interpretation, unless $L_1(1) = L_1(0)$, that is, the post-treatment covariate is unaffected by treatment.
- More on truncation by death
 - When the treatment increases survival, it may allow more weak individuals to survive compared to the control group.
 - Consequently, those with $L_1(1) = 1$ (survivors under treatment) may be systematically weaker than those with $L_1(0) = 1$ (survivors under control), highlighting that survival subsets under different treatments are not directly comparable.

Conditioning on the potential values of post-treatment covariates

➤ As mentioned earlier, why don't we simply ignore post-treatment covariates?

➤ Reasons

1. When post-treatment covariates introduces confounding effects:

- If a post-treatment covariates affects the outcome and is affected by treatment, it becomes a time-varying confounder.
- Ignoring it violates the exchangeability assumption, biasing your total effect estimate.

2. When selection bias occurs (e.g., Truncation by Death):

- If only a subset of individuals (e.g., survivors) have outcome data,
- And survival is influenced by treatment,
- Then the observed outcome is conditionally dependent on a post-treatment covariate (L_1).
 - You're comparing non-comparable groups unless you account for this.

3. When post-treatment covariates are used in outcome definitions:

- E.g., wage observed only if employed, or quality of life only if alive.
- Ignoring L_1 in such cases leads to estimands that are not well-defined.

Conditioning on the potential values of post-treatment covariates (cont.)

- Frangakis and Rubin (2002) suggests principal stratification (Part 4-3, monotonicity for IV)

$$\begin{cases} \tau(\mathbf{1}, \mathbf{1}) = \mathbb{E}(Y(1) - Y(0) | L_1(1) = \mathbf{1}, L_1(0) = \mathbf{1}) \\ \tau(\mathbf{1}, \mathbf{0}) = \mathbb{E}(Y(1) - Y(0) | L_1(1) = \mathbf{1}, L_1(0) = \mathbf{0}) \\ \tau(\mathbf{0}, \mathbf{1}) = \mathbb{E}(Y(1) - Y(0) | L_1(1) = \mathbf{0}, L_1(0) = \mathbf{1}) \\ \tau(\mathbf{0}, \mathbf{0}) = \mathbb{E}(Y(1) - Y(0) | L_1(1) = \mathbf{0}, L_1(0) = \mathbf{0}) \end{cases}$$

- Since $\{L_1(1), L_1(0)\}$ is unaffected by treatment, it can be treated as a baseline covariate.
 - In this case, $\tau(\mathbf{l}_1, \mathbf{l}_0)$ represents a subgroup (conditional) ATE.
- For subgroups where $L_1(1) = L_1(0)$:
 - The treatment does not alter the intermediate variable.
 - $\tau(\mathbf{1}, \mathbf{1})$ and $\tau(\mathbf{0}, \mathbf{0})$ capture **dissociative effects** (effects independent of the intermediate variable).
- For subgroups where $L_1(1) \neq L_1(0)$:
 - The treatment does affect the intermediate variable.
 - $\tau(\mathbf{l}_1, \mathbf{l}_0)$ reflects **associative effects**, showing how changes in L_1 are associated with changes in the outcome.

Conditioning on the potential values of post-treatment covariates (cont. 2)

➤ Truncation by Death

- The outcome (e.g., quality of life) is only defined for survivors.
- Therefore, the only meaningful subgroup effect is:

$$\tau(\textcolor{red}{1}, \textcolor{blue}{1}) = \mathbb{E}(Y(1) - Y(0) | L_1(1) = \textcolor{red}{1}, L_1(0) = \textcolor{blue}{1})$$

- This is known as the **Survivor Average Causal Effect (SACE)**—the treatment effect among those who would survive under both treatment and control.

➤ Unemployment

- Similar to truncation by death, wages are only defined for those who are employed.
- Thus, the relevant effect is again $\tau(\textcolor{red}{1}, \textcolor{blue}{1})$, interpreted as the **Employed Average Causal Effect**.
- Earlier methods like the Heckman Selection Model treated wages for the unemployed as missing.
- But under the potential outcomes framework, $\tau(\textcolor{red}{1}, \textcolor{blue}{1})$ offers a more meaningful causal interpretation.

➤ Surrogate Endpoint

- We want to evaluate treatment effects **via a surrogate** (e.g., CD4 count for long-term survival).
- A good surrogate must satisfy:
 - **Causal necessity**: If the treatment doesn't change the surrogate, it doesn't change the outcome.
→ Requires $\tau(\textcolor{red}{1}, \textcolor{blue}{1}) = 0$ and $\tau(\textcolor{red}{0}, \textcolor{blue}{0}) = 0$.
 - **Causal sufficiency**: If the treatment changes the surrogate, it changes the outcome.
→ Requires $\tau(\textcolor{red}{1}, \textcolor{blue}{0}) \neq 0$ and $\tau(\textcolor{red}{0}, \textcolor{blue}{1}) \neq 0$.


Back in the longitudinal setting

➤ Example: Time-varying Treatment in an HIV Study

To illustrate time-varying causal inference, consider a setting in which treatment may change at each time point. Let A_k denote a **binary treatment indicator** at month k , where $k = 0, 1, 2, \dots, 59$, representing a 5-year follow-up period.

For instance, in a cohort of individuals infected with HIV:


- $A_k = 1$ if the individual receives antiretroviral therapy (ART) in month k ,
- $A_k = 0$ if the individual does not receive treatment in that month.



- Time-varying treatment (A_0 and A_1): ART can be initiated, discontinued, or re-initiated across time.
- Time-varying confounders (L_0 and L_1): CD4 count, viral load, or adherence status may evolve and also affect future treatment decisions and outcomes.
- Outcome (Y): Could be a long-term clinical endpoint like progression to AIDS or death.
- Unmeasured confounder (U): e.g., adherence, health behavior

Treatment–confounder feedback

- Standard regression or stratification **fails** — because:
 1. Adjusting for a confounder that lies on the causal path blocks part of the treatment effect.
 2. If the confounder is also influenced by unmeasured variables, adjusting for it can introduce collider bias.
- L_1 is affected by prior treatment and affects future treatment → feedback loop.
- Even in randomized trials, if treatment depends on prior L_k , feedback arises. Standard models yield biased estimates of causal effects.



Hazard Function

- The hazard function describes the **instantaneous risk of an event occurring at a specific time, given that the individual has survived up to that time.**

It captures the rate at which events happen over time and is central to models like the Cox proportional hazards model.

- For a nonnegative random variable T denoting time to event, the hazard function $\lambda(t)$ is defined as:

$$\lambda(t) = \lim_{\Delta t \rightarrow 0} \frac{P(t \leq T < t + \Delta t | T \geq t)}{\Delta t} = \frac{f(t)}{S(t)}$$

where $f(t)$ is the probability density function of T and $S(t) = P(T > t)$ is the survival function.

For a survival outcome T

On the log hazard ratio scale: $\log(\lambda_T(1; t)) - \log(\lambda_T(0; t))$, where

$$\lambda_T(a; t) = \lim_{\Delta t \rightarrow 0} \frac{P(t \leq T(a) < t + h | T(a) > t)}{\Delta t}$$

The Hazards of Hazard Ratios

➤ **Example: Women's Health Initiative (WHI)** (Manson et al., 2003)

- Study Design: Randomized controlled trial comparing combined estrogen plus progestin therapy vs. placebo in over 16,000 postmenopausal women.
- Follow-up Duration: Average of 5.2 years before the trial was halted due to safety concerns.
- Primary Outcome: Coronary heart disease (CHD) events.

➤ Main results from Manson et al. (2003)

1. Single HR of 1.24, interpreted as a 24% increased risk of CHD with hormone therapy.
(weighted average over follow-up)
2. Year-specific HRs:
Year 1: 1.81; Year 2: 1.34; Year 3: 1.27; Year 4: 1.25; Year 5: 1.45; Year 6+: 0.70

→ **Does this look off to you?**

The Hazards of Hazard Ratios (cont.)

➤ Issue 1: Interpretational Problem

- If the study had ended after 1 year → $HR = 1.8$ → large harmful effect.
- After 5 years → $HR = 1.2$ → moderate effect.
- If it continued longer → possibly $HR = 1.0$ or less → no effect.

This demonstrates how the average HR depends on follow-up duration, not just on biology or treatment effect.

➤ Issue 2: Selection Bias (Depletion of Susceptibles)

- Susceptible women (those at higher CHD risk due to hormone therapy) were more likely to experience the event early.
- Over time, the remaining women in the treatment arm were less susceptible, biasing later HRs downward.
- The HR of 0.70 after year 5 might falsely suggest a protective effect, when in reality it's a result of selective survival.

While HRs can be useful in some contexts, they should not be the default causal estimand, especially in observational studies where time-varying confounding and selection effects are common.

References

Frangakis, C. E., & Rubin, D. B. (2002). Principal stratification in causal inference. *Biometrics*, 58(1), 21-29.

Hernán, M. A. (2010). The hazards of hazard ratios. *Epidemiology*, 21(1), 13-15.

Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., ... & Cushman, M. (2003). Estrogen plus progestin and the risk of coronary heart disease. *New England Journal of Medicine*, 349(6), 523-534.